Roundup: Top Pharma Companies Report Q4 Earnings, Highlighting Revenue Trends and Market Shifts

Image Credit: Adobe Stock Images/Kost9

Multiple pharma companies have released their 2024 Q4 earnings, highlighting total sales, operational growth, full-year sales growth, and increased investments.

Johnson & Johnson

Earlier this month, Johnson & Johnson (J&J) released its full Q4 earnings report. According to the company, its innovative medicine division grew by 7.5% outside of its COVID-19 vaccine. Treatments that supported this growth included Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine). Additionally, MedTech grew by 6.2%, primarily due to electrophysiology products.¹

“2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, chairman, CEO, Johnson & Johnson, in a press release. “As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure. With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson.”

Roche

Roche announced that during Q4, group sales grew by 7%; however, this rose to 9% when excluding COVID. The company’s pharmaceuticals division experienced an 8% growth, driven by a strong demand for Vabysmo (faricimab-svoa) for severe eye diseases, Phesgo (pertuzumab/trastuzumab/hyaluronidase) for breast cancer, Ocrevus (ocrelizumab) for multiple sclerosis, and Hemlibra (emicizumab-kxwh) for hemophilia A. Further, the diagnostics division grew by 4%, operating profit rose by 14%, and core earnings per share grew by 7%. However, International Financial Reporting Standards net income declined by 19% as a result of impairment charges related to Flatiron Health and Spark Therapeutics. The company noted key approvals, such as Vabysmo and Columvi (glofitamab-gxbm), the launch of the cobas Mass Spec system, and the acquisition of Poseida Therapeutics.²

“2024 was a strong year for Roche. In the fourth quarter, we continued our very positive momentum for the third consecutive quarter with Group sales growth of 9% (CER). Core earnings per share exceeded the guidance raised at half year,” said Thomas Schinecker, CEO, Roche, in a press release.

Teva

This week, Teva announced its second consecutive year of growth, including a 4% increase in revenue, resulting from sales of therapies such as Austedo (deutetrabenazine), Uzedy (risperidone), and Ajovy (fremanezumab), as well as and product rights sales, partially offset by a prior-year $500 million upfront payment for duvakitug. Further, gross profit rose 5% to $8.06 billion, with a margin increase to 48.7% due to favorable product mix. R&D prices increased by 5% while sales and marketing increased to 9%.³

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products. Focusing on rigorous execution of our Pivot to Growth strategy throughout the year, we continued to achieve important milestones in each of its four pillars, including surpassing the outlook for our key innovative products, growing our generics business across all segments, and accelerating our early-stage innovative pipeline, including the positive Phase IIb results for our duvakitug (anti-Tl1A) asset. These results pave the way for pivotal trials in Crohn’s disease and ulcerative colitis, as well as, potentially, other Immunological and fibrotic indications beyond, in collaboration with our partner, Sanofi,” said Richard Francis, president, CEO, Teva, in a press release.

Sanofi

Sanofi announced that in Q4, sales grew by 10.3%. Additionally, new launches rose by 56.5%, with Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] providing the most profit in that area. Further, vaccine sales grew by 10.8%. The company also highlighted four regulatory approvals, 21 submission acceptances, and eight positive Phase III readouts in its advanced pipeline. Closing out 2024, approvals for Dupixent (dupilumab) and Kevzara (sarilumab) in the EU were also of note.⁴

“We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales. We exceeded our business EPS guidance. In 2024, we announced an intention to sell a controlling stake in Opella consumer health, which will make Sanofi a focused, science-driven biopharma company. We increased R&D investments and achieved significant progress with our pipeline in 2024, including positive phase 3 study results for new medicines such as rilzabrutinib in rare diseases and tolebrutinib in multiple sclerosis. As we enter 2025, we expect continued, solid growth in sales and a strong rebound in earnings. We are also confident in the mid to long-term growth prospects of Sanofi, supported by ongoing launches, Dupixent (currently expected to reach sales of around €22 billion in 20307, in line with the current ambition), and expected future launches from our pipeline,” said Paul Hudson, CEO, Sanofi, in a press release.

Abbott

In Q4 2024, Abbott's sales increased 7.2% on a reported basis and 8.8% organically. This increases to 10.1% when excluding COVID testing-related sales. According to the company, overall sales reached $42.0 billion, up 4.6% on a reported basis and 7.1% organically. The company also revealed 15 success stories from its R&D, including new product approvals and treatment indications.⁵

"We finished the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest of the year," said Robert B. Ford, chairman, CEO, Abbott, in a press release. "We continued our track record for delivering on our commitments by achieving the upper end of our initial guidance ranges for 2024 and are well-positioned to deliver another year of strong growth in 2025."

References

1. Johnson & Johnson reports Q4 2024 and Full-Year 2024 results. Johnson & Johnson. January 22, 2025. Accessed January 30, 2025. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-2024-and-full-year-2024-results

2. [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth. Roche. January 29, 2025. Accessed January 30, 2025. https://www.roche.com/media/releases/med-cor-2025-01-30

3. Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth. Teva. January 29, 2025. Accessed January 30, 2025. https://www.tevapharm.com/news-and-media/latest-news/teva-delivers-second-consecutive-year-of-growth-announces-strong-financial-results-in-fourth-quarter-and/

4. Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025. Sanofi. January 30, 2025. Accessed January 30, 2025. https://www.sanofi.com/en/media-room/press-releases/2025/2025-01-30-06-30-00-3017713

5. Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook. Abbott. Accessed January 30, 2025. https://abbott.mediaroom.com/2025-01-22-Abbott-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Issues-2025-Financial-Outlook